Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)

Technology appraisal
Reference number: TA811
Published: 27 July 2022

History

Invitation to participate

Final scope (PDF 216 KB)

Published:

04 August 2021
Final stakeholder list (PDF 165 KB)

Published:

04 August 2021
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 310 KB)

Published:

04 August 2021
Equality impact assessment (Scoping) (PDF 119 KB)

Published:

04 August 2021

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope post referral (PDF 234 KB)

Published:

13 August 2020
Draft matrix post referral (PDF 162 KB)

Published:

13 August 2020